190 related articles for article (PubMed ID: 28825423)
1. Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation.
Kem WR; Olincy A; Johnson L; Harris J; Wagner BD; Buchanan RW; Christians U; Freedman R
Neuropsychopharmacology; 2018 Feb; 43(3):583-589. PubMed ID: 28825423
[TBL] [Abstract][Full Text] [Related]
2. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
[TBL] [Abstract][Full Text] [Related]
3. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia.
Tregellas JR; Tanabe J; Rojas DC; Shatti S; Olincy A; Johnson L; Martin LF; Soti F; Kem WR; Leonard S; Freedman R
Biol Psychiatry; 2011 Jan; 69(1):7-11. PubMed ID: 20728875
[TBL] [Abstract][Full Text] [Related]
4. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
[TBL] [Abstract][Full Text] [Related]
5. Initial phase 2 trial of a nicotinic agonist in schizophrenia.
Freedman R; Olincy A; Buchanan RW; Harris JG; Gold JM; Johnson L; Allensworth D; Guzman-Bonilla A; Clement B; Ball MP; Kutnick J; Pender V; Martin LF; Stevens KE; Wagner BD; Zerbe GO; Soti F; Kem WR
Am J Psychiatry; 2008 Aug; 165(8):1040-7. PubMed ID: 18381905
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.
Haig GM; Wang D; Zhao J; Othman AA; Bain EE
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 28922590
[TBL] [Abstract][Full Text] [Related]
7. 3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats.
Potasiewicz A; Hołuj M; Kos T; Popik P; Arias HR; Nikiforuk A
Neuropharmacology; 2017 Feb; 113(Pt A):188-197. PubMed ID: 27717880
[TBL] [Abstract][Full Text] [Related]
8. Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia.
Tregellas JR; Olincy A; Johnson L; Tanabe J; Shatti S; Martin LF; Singel D; Du YP; Soti F; Kem WR; Freedman R
Neuropsychopharmacology; 2010 Mar; 35(4):938-42. PubMed ID: 19956085
[TBL] [Abstract][Full Text] [Related]
9. Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.
Preskorn SH; Gawryl M; Dgetluck N; Palfreyman M; Bauer LO; Hilt DC
J Psychiatr Pract; 2014 Jan; 20(1):12-24. PubMed ID: 24419307
[TBL] [Abstract][Full Text] [Related]
10. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.
Zhang XY; Liu L; Liu S; Hong X; Chen DC; Xiu MH; Yang FD; Zhang Z; Zhang X; Kosten TA; Kosten TR
Am J Psychiatry; 2012 Sep; 169(9):974-81. PubMed ID: 22952075
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.
Haig GM; Bain EE; Robieson WZ; Baker JD; Othman AA
Am J Psychiatry; 2016 Aug; 173(8):827-35. PubMed ID: 26940805
[TBL] [Abstract][Full Text] [Related]
12. Effects of a nicotinic agonist on the Brief Psychiatric Rating Scale five-factor subscale model in schizophrenia.
Lewis AS; Olincy A; Buchanan RW; Kem WR; Picciotto MR; Freedman R
Schizophr Res; 2018 May; 195():568-569. PubMed ID: 29050790
[No Abstract] [Full Text] [Related]
13. α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia.
Freedman R
Annu Rev Med; 2014; 65():245-61. PubMed ID: 24111888
[TBL] [Abstract][Full Text] [Related]
14. Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice.
Simosky JK; Stevens KE; Kem WR; Freedman R
Biol Psychiatry; 2001 Oct; 50(7):493-500. PubMed ID: 11600102
[TBL] [Abstract][Full Text] [Related]
15. Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker.
Hashimoto K
Curr Pharm Des; 2015; 21(26):3797-806. PubMed ID: 26044974
[TBL] [Abstract][Full Text] [Related]
16. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.
Umbricht D; Keefe RS; Murray S; Lowe DA; Porter R; Garibaldi G; Santarelli L
Neuropsychopharmacology; 2014 Jun; 39(7):1568-77. PubMed ID: 24549101
[TBL] [Abstract][Full Text] [Related]
17. First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: Pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288.
Gee KW; Olincy A; Kanner R; Johnson L; Hogenkamp D; Harris J; Tran M; Edmonds SA; Sauer W; Yoshimura R; Johnstone T; Freedman R
J Psychopharmacol; 2017 Apr; 31(4):434-441. PubMed ID: 28196430
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.
Beinat C; Banister SD; Herrera M; Law V; Kassiou M
CNS Drugs; 2015 Jul; 29(7):529-42. PubMed ID: 26242477
[TBL] [Abstract][Full Text] [Related]
19. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
J Psychopharmacol; 2019 Jun; 33(6):688-699. PubMed ID: 30920339
[TBL] [Abstract][Full Text] [Related]
20. α7 Nicotinic Acetylcholine Receptor: A Potential Target in Treating Cognitive Decline in Schizophrenia.
Jones C
J Clin Psychopharmacol; 2018 Jun; 38(3):247-249. PubMed ID: 29505470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
